Non-small cell lung cancer (NSCLC) Clinical Trials in New Haven, CT
As of August 2026, 31 paid clinical trials are recruiting for Non-small cell lung cancer (NSCLC) in New Haven, Connecticut. Compensation typically covers time, travel, and study visits, and many studies also include study-related medical care at no cost.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Related specialties in New Haven
Filter results
31 clinical trials for Non-small cell lung cancer (NSCLC)
·Clear filters·Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Dose-Deescalated 3-Fraction Stereotactic Body Radiotherapy For Centrally Located Lung Cancer
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) to Tyrosine Kinase Inhibitor in Oligoprogressive Oncogenic Positive Non-Small Cell Lung Carcinoma
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
Top Research Study Locations in New Haven
Researchers run research studies in New Haven, CT at 25 active sites. The clinics below currently host the largest number of recruiting studies — each name is followed by the conditions they focus on most.
| Site | Specializes in | Active trials |
|---|---|---|
| Yale University | Acute Myeloid Leukemia, Alcohol Use Disorder, Stage IV Lung Cancer AJCC v8 | 246 |
| Yale Cancer Center | Advanced Solid Tumor, Advanced Solid Tumors, NSCLC | 67 |
| Yale New Haven Hospital | Ischemic Stroke, Multiple Myeloma, NAFLD | 61 |
| Yale University School of Medicine | Alzheimers Disease, Alzheimers Disease, Familial, Colorectal Cancer | 59 |
| Yale School of Medicine | Epilepsy, Epilepsy (Treatment Refractory), Hemoglobinopathies | 41 |
| Smilow Cancer Center/Yale-New Haven Hospital | Ovarian Carcinoma, Plasma Cell Myeloma, Advanced Hepatocellular Carcinoma | 20 |
| Yale | AML, MDS, Acute Gastrointestinal Bleeding | 12 |
| Yale-New Haven Hospital | Acute Ischemic Stroke, Acute Myeloid Leukemia, Anemia, Sickle Cell | 12 |
| Connecticut Mental Health Center | Borderline Personality Disorder, Alcohol Use, Alcohol Use Disorder | 11 |
| GSK Investigational Site | HIV Infections, Colonic Neoplasms, Gastrointestinal Neoplasms | 8 |
| Smilow Cancer Hospital at Yale New Haven | Advanced Solid Tumor, AML, AML With Mutated NPM1 | 8 |
| Yale Child Study Center | Speech, Anxiety Disorder of Adolescence, Autism | 7 |
| Yale New Haven Health | Chronic Kidney Diseases, Claudication, Critical Limb Ischemia | 7 |
| Musical Intervention Studios | COVID-19, Mental Health Issue, Alzheimer Disease | 6 |
| Smilow Cancer Hospital | Cancer, Sickle Cell Disease, Glioma, Malignant | 6 |
| Yale New Haven Health System | Aortic Stenosis, Heart Failure, ATTR Amyloidosis With Cardiomyopathy | 6 |
| Yale University School Of Medicine | Colorectal Neoplasms, Healthy Volunteers, Irritability Associated With Autism Spectrum Disorder | 6 |
| Yale University, Yale Cancer Center | Breast Cancer, Endometrial Cancer, Ovarian Cancer | 6 |
| BLOOM | COVID-19, Mental Health Issue | 5 |
| Clinical Trial Site | Breast Cancer, ER Positive Breast Cancer, Generalized Myasthenia Gravis | 5 |
| Smilow Cancer Hospital - Yale New Haven Health | Breast Cancer, Esophageal Cancer, Advanced Non-Small Cell Lung Cancer | 5 |
| Yale University Cancer Center | Advanced Solid Tumor, Advanced Solid Tumors, Anal Squamous Cell Carcinoma | 5 |
| Yale New Haven Children's Hospital | Antibiotic Stewardship, Failed or Difficult Intubation, Sequela, Intubation Complication | 4 |
| Yale University Yale Cancer Center | Advanced Solid Tumor, Advanced Solid Tumors, B Cell Lymphoma | 4 |
| Yale-New Haven Hospital-Yale Cancer Center | Advanced Breast Cancer, Breast Cancer, CRC | 4 |
Active & Upcoming Studies in New Haven (2026)
Recruiting trials in New Haven grouped by therapeutic area, drawn from ClinicalTrials.gov. Each bucket shows the most recent example studies.
Cancer & tumors (312 active studies)
- Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma · Phase 2 · National Cancer Institute (NCI)
- Unified Network for Integrated Fluid Collection at Yale · Yale University
Neurology & pain (46 active studies)
- COMparison Between Anakinra and Tocilizumab in NORSE - "COMBAT-NORSE" · Phase 3 · Yale University
- Psilocybin-Assisted Physical Therapy in Chronic Low Back Pain · Phase 2 · Yale University
Cardiovascular (39 active studies)
- Health-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For Health · Yale University
- Pulmonary Hypertension and Oxygen Saturation Targeting in Preterm Infants · University of Alabama at Birmingham
Diabetes & metabolic (36 active studies)
- Semaglutide Dose Effects on Metabolic and Stress Hormone, Craving and Alcohol Use Outcomes · Phase 1 · Yale University
- Glucose, Understanding, Integrated Digital Health, and Engagement (GUIDE) Study · Yale University
Mental health & behavior (26 active studies)
- Real-time Opioid Study · Yale University
- The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease · Phase 2 · Yale University
Vaccines (11 active studies)
HIV / STI (11 active studies)
- A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed · Phase 3 · ViiV Healthcare
- RESTORE Study R61 Phase: Recovery and Engagement for Stimulant Users on Re-entry · University of Texas Southwestern Medical Center
Pediatric (6 active studies)
Common conditions studied in New Haven
- Advanced Solid Tumor (22 active studies)
- Breast Cancer (20 active studies)
- Alcohol Use Disorder (16 active studies)
- Acute Myeloid Leukemia (13 active studies)
- Advanced Solid Tumors (12 active studies)
- Heart Failure (11 active studies)
Leading research sponsors in New Haven
- Yale University
- National Cancer Institute (NCI)
- Children's Oncology Group
- Merck Sharp & Dohme LLC
- SWOG Cancer Research Network
Frequently asked questions
How many paid clinical trials are currently recruiting in New Haven?
There are approximately 848 recruiting clinical trials in New Haven, Connecticut listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in New Haven pay participants?
Most recruiting trials in New Haven compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in New Haven?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in New Haven?
The most common conditions under active study in New Haven include Advanced Solid Tumor (22), Breast Cancer (20), Alcohol Use Disorder (16), Acute Myeloid Leukemia (13), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in New Haven?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in New Haven on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in New Haven?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in New Haven?
Recruiting research sites in New Haven include Yale University, Yale Cancer Center, Yale New Haven Hospital, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in New Haven right now?
The largest active categories in New Haven are Cancer & tumors (312), Neurology & pain (46), Cardiovascular (39). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.